The earnings call presented a mix of strategic achievements and significant challenges. The company highlighted strong strategic moves and synergies following the Akoya acquisition, a stable consumables revenue stream, and expansion into new market segments. However, these positives were overshadowed by considerable revenue declines, particularly in academic and pharma sales, alongside increased operating expenses and a significant drop in gross margin. The company's focus on long-term growth and cost savings offers a positive outlook, but current financial challenges are significant.

Company Guidance

During the Quanterix Corporation Q2 2025 earnings call, leadership provided guidance highlighting key financial metrics and strategic initiatives. The company reported total revenue of $24.5 million, reflecting a 29% decline year-over-year, attributed to temporary academic funding and biopharma spending headwinds. The acquisition of Akoya is anticipated to drive future growth, with synergy savings and cost reductions expected to reach approximately $85 million by 2026, 75% of which have already been achieved. Quanterix is targeting a breakeven financial position by 2026 and anticipates double-digit growth trajectories in its core markets. The combined company projects 2025 revenue between $130 million and $135 million, incorporating Akoya's results. The call emphasized strategic investments in proteomics, expanding market reach to a $5 billion sector, and the upcoming launch of the Simoa One platform. The company also reaffirmed its commitment to achieving cash flow positivity by 2026, while continuing to invest significantly in research and development to maintain its competitive edge.

Akoya Acquisition Completed

Quanterix completed the transformative Akoya acquisition, aiming for long-term growth and value creation through synergy savings and a stronger market position.

Strategic Revenue Growth Drivers

Investments in strategic drivers to support sustainable double-digit revenue growth and margin improvement, positioning for breakeven in 2026.

Synergy Savings Achieved

Quanterix expects to achieve approximately $85 million in synergy savings and cost reductions, with 75% of these savings already implemented.

Expansion of Addressable Market

Quanterix expanded its addressable market to $5 billion across neurology, immunology, and oncology, with a strong consumables revenue of approximately $100 million.

Strong Consumables Revenue

Consumables revenue was stable, approximately $100 million pro forma, demonstrating resilience in a challenging macro environment.

Simoa Platform Expansion

Launch of Simoa One by the end of 2025, expanding the addressable installed base by 20x to over 20,000 systems globally, creating substantial high-margin growth opportunities.

Alzheimer's Diagnostic Franchise Progress

Doubled test volumes, tripled revenues, and expanded international regulatory footprint with new partnerships, on track for Medicare pricing recommendation.

Quanterix (QTRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

QTRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.47 / -	-0.219	―	―	―
Aug 07, 2025	2025 (Q2)	-0.42 / -0.77	-0.25	-208.00% (-0.52)
May 12, 2025	2025 (Q1)	-0.43 / -0.53	-0.26	-103.85% (-0.27)
Mar 17, 2025	2024 (Q4)	-0.26 / -0.30	-0.33	9.09% (+0.03)
Nov 12, 2024	2024 (Q3)	-0.24 / -0.22	-0.21	-4.29% (>-0.01)
Aug 08, 2024	2024 (Q2)	-0.27 / -0.25	-0.16	-56.25% (-0.09)
May 07, 2024	2024 (Q1)	-0.31 / -0.26	-0.16	-62.50% (-0.10)
Feb 29, 2024	2023 (Q4)	-0.31 / -0.33	-0.5	34.00% (+0.17)
Nov 06, 2023	2023 (Q3)	-0.37 / -0.21	-0.95	77.89% (+0.74)
Aug 07, 2023	2023 (Q2)	-0.38 / -0.16	-0.67	76.12% (+0.51)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

QTRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$5.51	$4.75	-13.79%
May 12, 2025	$5.73	$4.64	-19.02%
Mar 17, 2025	$7.28	$7.15	-1.79%
Nov 12, 2024	$15.17	$12.40	-18.26%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Quanterix Corporation (QTRX) report earnings?

Quanterix Corporation (QTRX) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Quanterix Corporation (QTRX) earnings time?

Quanterix Corporation (QTRX) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is QTRX EPS forecast?

QTRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.47.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing